All of CombiGene’s board and management will subscribe for shares in the new issue.

CombiGene had a very intensive year in 2017, with three successful preclinical studies. Thanks to the positive results from these studies, CombiGene is now preparing for the next important step on our path to an approved drug via our collaboration with British CGT Catapult for development of a method for manufacturing our candidate drug, CG01.

To finance this development, CombiGene is now carrying out a preferential rights issue, in which the entire board is participating. Both Chairman Arne Ferstad and CEO Jan Nilsson are subscribing for more than their allotted shares in the issue.